Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Table 1

Patient characteristics.

Characteristic	All patients	GDB patients
Total	44	35
Male	22 (50%)	15 (43%)
Female	22 (50%)	20 (57%)
Age
Median	54.5	54
Range	24–75	39–72
ECOG
Median	0	0
Range	0-1	0-1
Tumor type
Leiomyosarcoma	20 (45%)	18 (51%)
Uterine	5	5
Nonuterine	15	13
Undifferentiated pleomorphic sarcoma	17 (39%)	11 (31%)
Angiosarcoma (liver, bone, soft tissue)	6 (14%)	5 (14%)
Pleomorphic liposarcoma	1 (2%)	1 (3%)
Prior treatment
Doxorubicin (or liposomal doxorubicin)	8	5
Ifosfamide	5	3
Dacarbazine	3	2
Sorafenib	2	1
None	34 (77%)	29 (83%)